E.g., 12/09/2022
E.g., 12/09/2022

MNA Rizqy and Minister Fitzgibbon honor the employees of bioMérieux Canada Inc. with the National Assembly Medal for their exceptional contribution during the COVID-19 pandemic

27 June, 2022

Montreal, QC, June 27, 2022 – bioMérieux, a major player in the field of in vitro diagnostics, is proud to announce that the 80 employees of its Canadian subsidiary have been honored by obtaining the medal of the National Assembly awarded for their distinguished commitment during the COVID-19 pandemic. This recognition is given by Mrs. Marwah Rizqy, Member of Parliament for St-Laurent and Mr. Pierre Fitzgibbon, Minister of Economy and Innovation.

bioMérieux receives Health Canada Approval for BIOFIRE® Blood Culture Identification 2 (BCID2) Panel for Rapid Molecular Bloodstream Infection Identification

24 May, 2022

Marcy-l’Etoile (France) – May 24, 2022 – bioMérieux a world leader in the field of in vitro diagnostics, announces that its BIOFIRE® Blood Culture Identification 2 (BCID2) Panel has received Health Canada approval. The BIOFIRE® BCID2 Panel for rapid molecular diagnostic of bloodstream infection includes several additional pathogens, an expanded list of antimicrobial resistance genes, and many revised targets compared to the existing BIOFIRE® BCID Panel.

bioMérieux strengthens its commitment to fight antimicrobial resistance with the acquisition of Specific Diagnostics, an innovative company focusing on fast AST solution

12 April, 2022

Marcy l’Étoile, France, April 12th 2022 – bioMérieux, a world leader in the field of in vitro diagnostics, announces that it has entered into an agreement to acquire Specific Diagnostics, a privately held U.S. based company that has developed a rapid antimicrobial susceptibility test (AST) system that delivers phenotypic AST directly from positive blood cultures. bioMérieux has held a minority stake in Specific Diagnostics since 2019, and the two companies had signed a co-distribution agreement covering the European market in 2021.

bioMérieux receives FDA 510(k) clearance for its VITEK® MS PRIME new MALDI-TOF mass spectrometry identification system

18 March, 2022

Marcy l’Etoile, France – March 18, 2022 — bioMérieux, a world leader in the field of in vitro diagnostics, announces that VITEK® MS PRIME, its new MALDI-TOF1 mass spectrometry identification system, has received 510(k) clearance from the U.S. Food and Drug Administration (FDA). This next generation system for routine microbial identification in minutes is now commercially available in countries that recognize CE-marking and in the United States.

bioMérieux molecular tests efficiently detect SARS-CoV-2 Omicron variant

02 December, 2021

As the incidence of infections with the SARS-CoV-2 Omicron variant (B.1.1. 529) continues to rise, there is much concern about diagnostic tests ability to efficiently detect this multi-mutated form of the COVID-19 virus.

bioMérieux announces CE-marking of the new MALDI-TOF mass spectrometry identification system: VITEK® MS PRIME

30 April, 2021

bioMérieux, a world leader in the field of in vitro diagnostics, has announced the CE-marking of VITEK® MS PRIME, the next generation of the VITEK® MS MALDI-TOF1 mass spectrometry system for routine microbial identification in minutes.

bioMérieux – First-Quarter 2021 Business Review

27 April, 2021

bioMérieux, a world leader in the field of in vitro diagnostics, today releases its business review for the three months ended March 31, 2021.

BIOFIRE® Respiratory 2.1 (RP2.1) Panel with SARS-CoV-2 obtains De Novo FDA Authorization

18 March, 2021

Marcy l’Étoile (France) – bioMérieux, a world leader in the field of in vitro diagnostics, today announced that BioFire Diagnostics, its subsidiary specialized in molecular syndromic infectious disease testing, has received U.S. Food and Drug Administration (FDA) De Novo authorization for the BIOFIRE® RP2.1 Panel. 

Pioneering diagnostics